Three-dimensional spatial configuration of tumour cells confers resistance to chemotherapy independent of drug delivery

Journal of Tissue Engineering and Regenerative Medicine

Volumn 10, Issue 8, 2016, Pages 637-646

  Tan, Pamela H S ^a   Chia, Su Shin ^a   Toh, Siew Lok ^a   Goh, James C H ^a   Nathan, Saminathan Suresh ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cell cycle arrest; cell proliferation; chemotherapy; cyclin B1; cytotoxicity; E2F1; silk; three dimensional tumour model

Indexed keywords

ANIMALS; CHEMOTHERAPY; COPYRIGHTS; DRUG DELIVERY; POLYMERASE CHAIN REACTION; PROTEINS; SILK; TUMORS;

3D SCAFFOLDS; CELL-CYCLE ARREST; CYCLIN B1; CYCLINS; E2F1; SILK; SPATIAL CONFIGURATION; THREE-DIMENSIONAL TUMOR MODEL; TUMOR MODELS; TUMOUR CELLS;

CELL PROLIFERATION;

CISPLATIN; CYCLIN B1; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN P21; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; BOMBYX MORI; CANCER RESISTANCE; DNA CONTENT; DOWN REGULATION; DRUG CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTING; G1 PHASE CELL CYCLE CHECKPOINT; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SAOS 2 CELL LINE; TISSUE CULTURE; TUMOR CELL; TUMOR MODEL; U2OS CELL LINE; UPREGULATION;

EID: 85027927406     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1800     Document Type: Article

References (40)

1. Altman GH. Diaz F, Jakuba C et al. 2003; Silk-based biomaterials. Biomaterials 24(3): 401–416.
2. Besson A, Assoian RK, Roberts JM. 2004; Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer 4(12): 948–955.
3. Biswas AK, Johnson DG. 2012; Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. Cancer Res 72(1): 13–17.
4. Comoglio PM, Trusolino L. 2005; Cancer: the matrix is now in control. Nat Med 11(11): 1156–1159.
5. Debnath J, Muthuswamy SK, Brugge JS. 2003; Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30(3): 256–268.
6. Domingo-Sananes MR, Kapuy O, Hunt T et al. 2011; Switches and latches: a biochemical tug-of-war between the kinases and phosphatases that control mitosis. Phil Trans R Soc B Biol Sci 366(1584): 3584–3594.
7. el-Deiry WS, Tokino T, Velculescu VE et al. 1993; WAF1, a potential mediator of p53 tumor suppression. Cell 75(4): 817–825.
8. Engelmann D, Putzer BM. 2012; The dark side of E2F1: in transit beyond apoptosis. Cancer Res 72(3): 571–575.
9. Fischbach C, Chen R, Matsumoto T et al. 2007; Engineering tumors with 3D scaffolds. Nat Methods 4(10): 855–860.
10. Gartel AL, Najmabadi F, Goufman E et al. 2000; A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription. Oncogene 19(7): 961–964.
11. 1 cyclin-dependent kinases. Cell 75(4): 805–816.
12. Hartman O, Zhang C, Adams L et al. 2009; Microfabricated electrospun collagen membranes for 3D cancer models and drug screening applications. Biomacromolecules 10(8): 2019–2032.
13. Hecquet B, Caty A, Fournier C et al. 1987; Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin. Bull Cancer 74(4): 433–436.
14. Huang CP, Lu J, Seon H et al. 2009; Engineering microscale cellular niches for three-dimensional multicellular co-cultures. Lab Chip 9(12): 1740–1748.
15. Hutmacher DW, Horch RE, Loessner D et al. 2009; Translating tissue engineering technology platforms into cancer research. J Cell Mol Med 13(8A): 1417–1427.
16. Hutmacher DW, Loessner D, Rizzi S et al. 2010; Can tissue engineering concepts advance tumor biology research? Trends Biotechnol 28(3): 125–133.
17. Ki CS, Park SY, Kim HJ et al. 2008; Development of 3D nanofibrous fibroin scaffold with high porosity by electrospinning: implications for bone regeneration. Biotechnol Lett 30(3): 405–410.
18. Kim JB. 2005; Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15(5): 365–377.
19. Kim YJ, Bae HI, Kwon OK et al. 2009; Three-dimensional gastric cancer cell culture using nanofiber scaffold for chemosensitivity test. Int J Biol Macromol 45(1): 65–71.
20. Kundu SC, Kundu B, Talukdar S et al. 2012; Invited review: non-mulberry silk biopolymers. Biopolymers 97(6): 455–467.
21. Kwon H, Kim HJ, Rice WL et al. 2010; Development of an in vitro model to study the impact of BMP-2 on metastasis to bone. J Tissue Eng Regen Med 4(8): 590–599.
22. Lee J, Cuddihy MJ, Kotov NA. 2008; Three-dimensional cell culture matrices: state of the art. Tissue Eng B Rev 14(1): 61–86.
23. Martin WM, McNally NJ. 1980; Cytotoxicity of adriamycin to tumour cells in vivo and in vitro. Br J Cancer 42(6): 881–889.
24. Miller BE, Miller FR, Heppner GH. 1985; Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel cultures. Cancer Res 45(9): 4200–4205.
25. Nathan SS, DiResta GR, Casas-Ganem JE et al. 2005; Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 11(6): 2389–2397.
26. Ong S-M, Zhao Z, Arooz T et al. 2010; Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 31(6): 1180–1190.
27. Padron JM, van der Wilt CL, Smid K et al. 2000; The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol 36(2–3): 141–157.
28. Pampaloni F, Reynaud EG, Stelzer EHK. 2007; The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8(10): 839–845.
29. Provenzano PP, Keely PJ. 2011; Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J Cell Sci 124(8): 1195–1205.
30. Romanov VS, Pospelov VA, Pospelova TV. 2012; Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochemistry (Mosc) 77(6): 575–584.
31. Roncoroni L, Elli L, Bardella MT et al. 2010; Cytogenetic characterization and cell cycle analysis of three human colon adenocarcinoma cell lines: comparison between two- and three-dimensional cell culture systems. Cancer Invest 28(1): 7–12.
32. Storch K, Eke I, Borgmann K et al. 2010; Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res 70(10): 3925–3934.
33. Talukdar S, Mandal M, Hutmacher DW et al. 2011; Engineered silk fibroin protein 3D matrices for in vitro tumor model. Biomaterials 32(8): 2149–2159.
34. Tan PH, Aung KZ, Toh SL et al. 2011; Three-dimensional porous silk tumor constructs in the approximation of in vivo osteosarcoma physiology. Biomaterials 32(26): 6131–6137.
35. Verbridge SS, Chandler EM, Fischbach C. 2010; Tissue-engineered three-dimensional tumor models to study tumor angiogenesis. Tissue Eng A 16(7): 2147–2152.
36. Wang Y, Kim HJ, Vunjak-Novakovic G et al. 2006; Stem cell-based tissue engineering with silk biomaterials. Biomaterials 27(36): 6064–6082.
37. Xing H, Wang S, Hu K et al. 2005; Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J Cancer Res Clin Oncol 131(8): 511–519.
38. Xu F, Burg KJ. 2007; Three-dimensional polymeric systems for cancer cell studies. Cytotechnology 54(3): 135–143.
39. Zhang X, Wang W, Yu W et al. 2005; Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing. Biotechnol Progr 21(4): 1289–1296.
40. Zhou CZ, Confalonieri F, Jacquet M et al. 2001; Silk fibroin: structural implications of a remarkable amino acid sequence. Proteins 44(2): 119–122.